Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Videos

IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM

 

Robert Rifkin, MD, Rocky Mountain Cancer Center, Denver, Colorado, discusses results from the TOURMALINE-MM2 trial which compared ixazomib, lenalidomide, and dexamethasone (IRd) versus placebo-Rd for transplant-ineligible patients with newly diagnosed MM.

These results were presented at the virtual 62nd ASH Annual Meeting and Exposition.


Advertisement

Advertisement

Advertisement